Putting a POC Troponin to the Test

Independent verification shows strong precision and concordance with lab assays across clinical thresholds.

By
Julie Greenbaum
February 5, 2026
3 min

MDSpire News

Objective:

To verify the analytical performance and concordance of the QuidelOrtho TriageTrue point-of-care high-sensitivity troponin I assay in patients assessed for myocardial infarction.

Approach:

Key Findings:

Intra-assay precision CVs were 25% and 12.2% at mean concentrations of 2.4 ng/L and 8.5 ng/L, respectively, with overall performance metrics indicating adequacy.
Hemolysis caused minimal interference up to 10 g/L, exceeding the manufacturer's claim.
Correlation coefficients with other assays ranged from 0.89 to 0.99, except for Roche hs-TnT assay (0.79).
All 116 comparisons with secondary analyzers met acceptable limits.

Interpretation:

The hs-TnI assay on the TriageTrue demonstrates adequate performance for clinical use, supporting its integration into clinical pathways based on the findings.

Limitations:

Logistical constraints in obtaining suitable whole blood EDTA samples limited targeted sampling at specific troponin I levels, impacting the study's findings.

Conclusion:

The assay's analytical performance supports its use in emergency care and low-resource settings, aligning with manufacturer claims and emphasizing its clinical significance.